Literature DB >> 1385566

Plasma concentration--effect relationships for felodipine: a meta analysis.

E Blychert1, B Edgar, D Elmfeldt, T Hedner.   

Abstract

The plasma concentration versus antihypertensive effect relationship for the calcium antagonist felodipine was investigated in 67 patients with hypertension and 21 healthy subjects by use of the Emax model. No consistent effect of felodipine on blood pressure was observed in the healthy subjects. In patients with hypertension the plasma drug concentration and blood pressure versus time curves mirrored each other, indicating a close relationship between concentration and effect. The maximum effect (Emax) model fitted the diastolic blood pressure data of most patients, but the model was less often applicable in patients with low initial diastolic blood pressure levels. The average Emax values and the plasma felodipine concentration needed to obtain 50% of Emax for the patients with hypertension were 29 mm Hg and 8 nmol/L, respectively. The Emax values increased with increasing initial diastolic blood pressure levels but were similar in patients with high and low plasma felodipine concentrations. Age had negligible influence on the antihypertensive response to felodipine when compensation was made for the plasma concentrations.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1385566     DOI: 10.1038/clpt.1992.105

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

Review 1.  Concentration-effect analysis of antihypertensive drug response. Focus on calcium antagonists.

Authors:  R Donnelly; H L Elliott; P A Meredith
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

Review 2.  Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.

Authors:  G K Dresser; J D Spence; D G Bailey
Journal:  Clin Pharmacokinet       Date:  2000-01       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of nifedipine. Implications for the care of the elderly.

Authors:  H L Elliott; P A Meredith
Journal:  Drugs Aging       Date:  1997-12       Impact factor: 3.923

Review 4.  Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

5.  A comparative assessment of amlodipine and felodipine ER: pharmacokinetic and pharmacodynamic indices.

Authors:  A D Bainbridge; O Herlihy; P A Meredith; H L Elliott
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug-Drug Interaction Modeling.

Authors:  Laura Maria Fuhr; Fatima Zahra Marok; Maximilian Mees; Felix Mahfoud; Dominik Selzer; Thorsten Lehr
Journal:  Pharmaceutics       Date:  2022-07-15       Impact factor: 6.525

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.